Related Experiment Video
Updated: May 10, 2026

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
Published on: April 6, 2017
Intranasal ipratropium bromide for the common cold.
Zaina H AlBalawi1, Sahar S Othman, Khalid Alfaleh
1Department of Medicine, University of Alberta, Edmonton, Canada. Zaina.albalawi@ualberta.ca.
Intranasal ipratropium bromide (IB) effectively reduces runny nose in common cold patients, but does not improve nasal congestion. While side effects like nasal dryness occurred more frequently with IB, they were generally mild and temporary.
Area of Science:
- Medical Research
- Pharmacology
- Clinical Trials
Background:
- The common cold is a prevalent illness with significant economic impact.
- Current treatments focus on symptomatic relief as no cure exists.
- Intranasal ipratropium bromide (IB) is being investigated for its efficacy in managing cold symptoms.
Purpose of the Study:
- To evaluate the effectiveness of intranasal ipratropium bromide (IB) compared to placebo or no treatment.
- Primary outcomes included severity of rhinorrhoea and nasal congestion.
- Secondary outcomes assessed overall improvement and adverse effects.
Main Methods:
- Systematic review and meta-analysis of randomized controlled trials (RCTs).
- Searched multiple databases including CENTRAL, MEDLINE, EMBASE, AMED, Biosis, and LILACS.
- Data extraction and quality assessment were performed independently by two reviewers.
Main Results:
- Seven RCTs with 2144 participants were included.
- IB significantly reduced rhinorrhoea severity compared to placebo.
- No significant effect on nasal congestion was observed; however, side effects were more frequent in the IB group.
Conclusions:
- Intranasal ipratropium bromide (IB) shows potential for alleviating runny nose in common colds.
- IB does not improve nasal congestion and is associated with increased, though generally well-tolerated, side effects.
- Further high-quality trials are needed to confirm IB's effectiveness and safety profile.
Related Concept Videos
Drugs Used in Upper Respiratory Disorders: Overview
Antihistamines (e.g., Benadryl) block histamines from binding. Histamines are chemicals released during an allergic reaction in the body. As a...
Upper Respiratory Drugs: Decongestants
Most decongestants are readily available over-the-counter in various...
Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by anesthetizing...
Antiasthma Drugs: Muscarinic Receptor Antagonists
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
Cholinergic Antagonists: Pharmacokinetics
Cholinergic Antagonists: Therapeutic Uses
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal secretions in common...
